- Home
- NEGG vs CABA Comparison
NEGG vs CABA Comparison
Compare NEGG & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- CABA
- Stock Information
- Founded
- NEGG 2001
- CABA 2017
- Country
- NEGG United States
- CABA United States
- Employees
- NEGG N/A
- CABA N/A
- Industry
- NEGG Other Specialty Stores
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NEGG Consumer Discretionary
- CABA Health Care
- Exchange
- NEGG Nasdaq
- CABA Nasdaq
- Market Cap
- NEGG 122.3M
- CABA 118.8M
- IPO Year
- NEGG 2010
- CABA 2019
- Fundamental
- Price
- NEGG $11.38
- CABA $1.79
- Analyst Decision
- NEGG
- CABA Strong Buy
- Analyst Count
- NEGG 0
- CABA 8
- Target Price
- NEGG N/A
- CABA $18.88
- AVG Volume (30 Days)
- NEGG 1.1M
- CABA 2.5M
- Earning Date
- NEGG 04-28-2025
- CABA 08-07-2025
- Dividend Yield
- NEGG N/A
- CABA N/A
- EPS Growth
- NEGG N/A
- CABA N/A
- EPS
- NEGG N/A
- CABA N/A
- Revenue
- NEGG $1,235,576,000.00
- CABA N/A
- Revenue This Year
- NEGG N/A
- CABA N/A
- Revenue Next Year
- NEGG N/A
- CABA N/A
- P/E Ratio
- NEGG N/A
- CABA N/A
- Revenue Growth
- NEGG N/A
- CABA N/A
- 52 Week Low
- NEGG $3.32
- CABA $0.99
- 52 Week High
- NEGG $26.40
- CABA $9.25
- Technical
- Relative Strength Index (RSI)
- NEGG 62.60
- CABA 47.69
- Support Level
- NEGG $8.95
- CABA $1.56
- Resistance Level
- NEGG $12.75
- CABA $2.02
- Average True Range (ATR)
- NEGG 2.28
- CABA 0.24
- MACD
- NEGG 0.15
- CABA -0.06
- Stochastic Oscillator
- NEGG 51.86
- CABA 22.33
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.